Patients with resolved atrial fibrillation have an increased risk for stroke or transient ischemic attack.
According to research presented at the 2018 American Heart Association's Epidemiology and Prevention/Lifestyle and Cardiometabolic Health Scientific Sessions in New Orleans.
The USPSTF has found that the current evidence is inadequate to assess the benefits and harms of screening with ECG for atrial fibrillation and cardiovascular disease in older adults.
Many direct acting oral anticoagulants may be more beneficial than warfarin.
Dual therapy with dabigatran and a P2Y12 inhibitor resulted in a lower risk of bleeding events compared with triple therapy with warfarin, a P2Y12 inhibitor, and aspirin.
The researchers found that concurrent use of amiodarone, fluconazole, rifampin, and phenytoin was associated with increased risk of major bleeding compared with the use of NOACs alone.
Researchers found that 16% of patients received doses inconsistent with US Food and Drug Administration labeling.
Compared with individuals reporting chocolate intake less than once per month, the rate of AF was lower for people consuming chocolate regularly.
Anticoagulation with dabigatran was associated with fewer bleeding complications compared with warfarin among patients undergoing ablation for atrial fibrillation.
Drinking small amounts of alcohol may increase the risk of atrial fibrillation.
Non-vitamin K antagonist oral anticoagulants perform similarly to warfarin for patients with atrial fibrillation.
Women with atrial fibrillation are at higher risk for cardiovascular disease, stroke, and death.
Multiple considerations come into play when choosing anticoagulant therapy for a patient with atrial fibrillation, a condition that greatly increases the risk for stroke.
Incident atrial fibrillation in older men can be predicted by central sleep apnea but not by obstructive apnea or hypoxemia.
The American College of Cardiology has published a guideline for the management of supraventricular tachycardia (SVT) in adult patients.
Anticoagulants are associated with an increased risk for bleeding, but for most patients, the benefits outweigh the bleeding risk.
Antithrombotic therapy is consistently recommended for most patients with atrial fibrillation and until recently warfarin, a vitamin K antagonist, has been the antithrombotic of choice.
In patients with atrial fibrillation but no heart failure, digoxin increases the risk of death and hospitalization.
Patients were taught to identify atrial fibrillation by measuring the peripheral pulse at the radial artery to prevent a second stroke.
After listening to a patient, this clinician urged an in-person visit that led to an ED admission for atrial fibrillation and heart failure.
Recommendations provide guidance for new medications, use of radiofrequency ablation.
Intensive intervention results in more weight loss, greater reduction in symptom burden.
Medication, ablation or rate control for a patient with first onset of atrial fibrillation?
The FDA has approved the oral anticoagulant drug apixaban (Eliquis) to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Patients with atrial fibrillation treated with rivaroxaban had a lower risk for intracranial hemorrhage than those treated with warfarin.
How often should follow-up ECG be performed on a pregnant patient with atrial fibrillation (AF) that resolves with medication that is then discontinued?
Atrial fibrillation (AF) affects an estimated 2.3 million Americans and is becoming more widespread as the population ages. Read about guideline changes that simplify treating AF in primary care.